(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

Swiss pharma company Roche ... FDA Priority Review status for a Perjeta (pertuzumab) regimen to be used before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

The green light comes after a six-month priority review by the FDSA and is a big step up for Roche’s drug, which has the opportunity to build a presence in breast cancer ahead of earlier-to ...

The FDA has cleared Delcath Systems to start a phase 2 trial for Hepzato in liver-dominant metastatic breast cancer. The trial will compare Hepzato plus standard care against standard care alone in ...

A study involving an experimental cancer drug being developed by Roche Holding (RHHBY, ROG.VX) showed it delayed disease progression in women with a specific type of breast cancer compared to ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial-intelligence-powered analysis to provide what the company says could ...